Denali Therapeutics Inc. (DNLI) stock is soaring 5.33% in pre-market trading on Monday, following Oppenheimer analyst Jay Olson's reaffirmation of a Buy rating for the company. The analyst has set a price target of $35.00 for Denali Therapeutics, signaling strong confidence in the company's future prospects.

Denali Therapeutics is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The positive analyst rating from Oppenheimer, a respected financial services firm, suggests that the company's pipeline and strategic direction are viewed favorably by market experts. This vote of confidence is likely driving investor optimism and contributing to the stock's significant pre-market gains.

The maintained Buy rating and the substantial price target could attract more investor attention to Denali Therapeutics. As the market opens, investors will be watching closely to see if the pre-market surge continues and whether the stock can sustain its momentum throughout the trading session. The analyst's positive outlook may also prompt other investors to reassess their positions on DNLI, potentially leading to increased trading volume and further price movements in the coming days.